THE FDA APPROVED THE IMMUNE CHECKPOINT INHIBITOR PEMBROLIZUMAB IN COMBINATION AND AS A SINGLE AGENT FOR ADVANCED CERVICAL CANCER The U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with chemotherapy,...
THE FDA APPROVED A NEW TYPE OF CANCER INHIBITOR FOR CERTAIN PATIENTS WITH A HIGH RISK OF RECURRENCE The U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio) with endocrine therapy for certain patients...
THE FDA APPROVED THE FIRST CAR-T CELL THERAPY FOR CERTAIN PATIENTS WITH this aggressive form of LEUKEMIA The U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (Tecartus) for certain adult patients with B-cell...
THE FDA GRANTED ACCELERATED APPROVAL TO A NEW THERAPY FOR ADVANCED CERVICAL CANCER The U.S. Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tidvak) for patients with cervical cancer that has...
The FDA approved a tyrosine kinase inhibitor for certain patients with thyroid cancer. The U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older...
The FDA granted accelerated approval to a new targeted therapeutic and companion diagnostic test for certain adult patients with lung cancer. The U.S. Food and Drug Administration (FDA) granted accelerated approval to mobocertinib (Exkivity)...
THE FDA GRANTED ACCELERATED APPROVAL TO ZANUBRUTINIB FOR CERTAIN ADULTS WITH MARGINAL ZONE LYMPHOMA The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa) for certain adult patients with marginal zone...
The FDA approved zanubrutinib, a tyrosine kinase inhibitor, for this form of non-Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) approved zanubrutinib (Brukinsa) for adult patients with Waldenström macroglobulinemia, a slow-growing form of...
The U.S. FDA approved a molecularly targeted therapeutic to treat certain patients with cholangiocarcinoma. The U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic ivosidenib (Tibsovo) for certain patients with cholangiocarcinoma—bile duct...
The U.S. FDA granted accelerated approval to an immunotherapeutic and a companion diagnostic test to treat certain cancer patients whose tumors have a specific biomarker. The U.S. Food and Drug Administration (FDA) granted accelerated approval to...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now